Kornimate/medical-research-clean huggingface dataset:
trastuzumab for her2 positive relapsed/refractory b-acute lymphoblastic leukemia (b-all)

Conditions: Relapsed/Refractory Leukemia

Summary: this is a multicenter open-label phase ii trial of trastuzumab in patients with her2 positive b-all in relapse, or with refractory disease. herceptin is administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or till progression. response and her2 expression are assessed each month by bone marrow aspirate.


Eligibility criteria:
inclusion criteria: * age \> 18 years * b-all in relapse * refractory b-all-performance status of 0-2 on the eastern cooperative oncology group scale * adequate hepatic and renal functions (ast or alt \<= 5 times the upper limit of normal creatinine \< 2 times the upper limit of normal) * \> 20% blasts in bone marrow, * \> 30% of bone marrow blast population her2 positive as assessed by immunophenotyping exclusion criteria: * previous treatment by trastuzumab * fevg \< 50%

Keywords: relapsed/refractory her2 positive b-all trastuzumab
french adult primary immune thrombocytopenia

Conditions: Thrombocytopenia

Summary: primary immune thrombocytopenia (itp) is rare. first-line treatment is corticotherapy. then, several second-line treatments (slt) are available: splenectomy, off-label rituximab and thrombopoietin-receptor agonists since 2009. the compared efficacy and safety on clinical events in the long-term are unknown. the main objective of the faith study is to build the cohort of all treated adult persistent (≥3 months) primary itp patients in france, to assess the benefit-to-risk ratio of slt in real-life practice. data source is the database of french health insurance system (sniiram) which covers the entire french population. it collects demographic, chronic disease, hospitalization and drug dispensing data. all patients with itp were extracted from 2009 to 2012, and then every year for 10 years. the investigator will build the cohort from raw data. outcomes (death, hospitalization, drug dispensing) will be compared according to slt, with controls from the general population and untreated patients.


Eligibility criteria:
inclusion criteria: * incident case of immune thrombocytopenia or control patient exclusion criteria: * patient not registered in the database between 2009 and 2012

Keywords: disease epidemiology risk assessment drug utilisation study effectiveness evaluation
telerehabilitation in people with long covid

Conditions: COVID-19

Summary: the aim of our study is to investigate the effectiveness of telerehabilitation in post-covid patients.

decreased exercise capacity, persistent dyspnea and easily fatigue are found in some post-covid patients. telerehabilitation has been developed in cardiac and pulmonary diseases such as coronary artery disease and chronic obstructive pulmonary disease for years with good clinical outcomes. however, little is known about the effectiveness of home-based telerehabilitation among post-covid patients. thus, we want to investigate the effectiveness of telerehabilitation among post-covid patients, including cardiorespiratory fitness, physical activity amounts, health related quality of life and sleep quality.

Eligibility criteria:
inclusion criteria: individuals who had been diagnosed with covid-19 positive and whose last pcr test or rapid antigen test was negative with the following criteria: * aged between 20 to 80 years old * persistent symptoms at least 4 weeks after recovery from covid-19 infection, including any of the following symptoms: dyspnea, fatigue, cough, headache, chest tightness, palpitations, loss of smell, anxiety, insomnia, brain fog or joint pain * able to speak and understand mandarin * able to walk including those who need the walking aid * had mobile phones and could easily access the internet exclusion criteria: * a history of chronic obstructive pulmonary disease or other respiratory diseases * a history of arrhythmia,cancer, end-stage renal disease with dialysis, being diagnosed with mental illness, recent stroke within 6 months * inability to participate because of comorbid neurological or musculoskeletal conditions that produce moderate to severe physical disability * need all day oxygen support

Keywords: post-covid telerehabilitation
effect of eecp on anterior ischemic optic neuropathy

Conditions: Anterior Ischemic Optic Neuropathy

Summary: enhanced external counterpulsation(eecp) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. the present study aims to investigate the effect of eecp on anterior ischemic optic neuropathy.

patients with anterior ischemic optic neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus eecp therapy besides standard medical treatment.

Eligibility criteria:
inclusion criteria: * ischemic optic neuropathy * within 1 month exclusion criteria: * hemorrhagic disease * thrombophlebitis or infection lesions * severe hypertensive patients * atrial fibrillation * aortic regurgitation

Keywords: visual acuity artery flow velocity enhanced external counterpulsation ischemic optic neuropathy
topical bevacizumab for preventing recurrent pterygium

Conditions: Pterygium; Bevacizumab; VEGF; Anti-VEGF

Summary: the purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.

a pterygium is a degenerative and proliferative fibrovascular disorder of the ocular surface. patients may be asymptomatic, irritation, decreased vision, diplopia or limit ocular movement. the mainstay treatment is surgical removal of the head, neck and body of the pterygium. however, if there is no adjunctive treatment, the recurrence is unacceptably high which is 63% in general. various adjunctive measures are applied to prevent recurrence including use of mitomycin c, beta-irradiation and surgical methods such as conjunctival and amniotic membrane graft. however, each method has its advantages and disadvantages. the histologic finding of recurrent pterygium often has aggressive fibrovascular growth. vascular endothelial growth factor(vegf)has been detected in increased amounts in pterygium tissue, compared with normal conjunctiva and it is also correlated with post-operative recurrence. bevacizumab, an anti-vegf, binds to vegf and prevents the interaction of vegf to its receptors on the surface of vascular endothelial cells. administration of bevacizumab leads to inhibition of endothelial cell proliferation and new blood vessel formation. even though there are reported the efficacy of topical bevacizumab in inhibiting the impending recurrent pterygium, there is no study for preventing recurrence after primary pterygium removal. we conduct a prospective, randomized, double-masked, controlled trial to evaluate the efficacy of topical bevacizumab 0.05% eye drops for preventing recurrence in primary pterygium.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (g.n.) * patients with pterygium who understand and can follow the study protocol. * patients of age more than 30 years exclusion criteria: * patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing. * patients who are pregnancy or lactation. * patients who have a history of allergy to bevacizumab. * patients who have a history of allergy to steroid eye drops

Keywords: pterygium recurrent pterygium bevacizumab vegf anti-vegf
the effect of education on decreasing the prevalence and severity of neck and shoulder pain

Conditions: Korean; Male; Adolescents

Summary: neck and shoulder pain (nsp) is fairly common among high school students in korea. presumably, the high prevalence of nsp in korean adolescents is a consequence of an inappropriate static position for a prolonged period of time. we suspect that proper education and posture correction for korean adolescents may decrease the prevalence or severity of nsp. although several studies have focused on the etiology of nsp during adolescence, few studies have addressed the management or prevention of nsp in adolescents, despite its high prevalence in this age group. the aims of this prospective study was to identify the effects of education, in terms of recognition of this issue and posture correction, on prevalence and severity of nsp in korean adolescents


Eligibility criteria:
inclusion criteria: * high school students exclusion criteria: * deny to participate

Keywords: education neck pain shoulder pain prevalence associated factors students
the c-mic-ii follow-up study

Conditions: Systolic Left Ventricular Dysfunction

Summary: the c-mic system is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart. target patients for this study are patients who have received the device in a prior study.

the c-mic system is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart. the therapy with the c-mic system is intended to take 6 months. the c-mic system consists of four parts, of which three are implanted: a transvenous and an epicardial lead and a power source to which the leads are connected. both leads have the function to transmit micro-current to the heart. a portable user terminal (put) is needed for programming and readout of the data recorded by the implantable microcurrent device (imd). target patients of the c-mic system at the time of implantation and inclusion in the c-micii study were patients with idiopathic dilative cardiomyopathy (nyha class iii - nyha class who have systolic left ventricular dysfunction despite adequate therapy of heart failure. target patients for this study are patients who have received the device in a prior study.

Eligibility criteria:
inclusion criteria: * patients who have received a c-mic system during the c-mic-ii study. * informed consent in writing from the patient. exclusion criteria: * patients who are unwilling or unable to participate in the study visits. * vulnerable patients.
trail to investigate the effectiveness of coseal in reducing adhesions following the kasai hepatoportoenterostomy for biliary atresia

Conditions: Biliary Atresia

Summary: the investigators plan to invite all children in the uk with biliary atresia, treated at the three national centres (birmingham, kings college and leeds), over a three year period to take part in a randomised control study. the investigators aim to determine the effectiveness of coseal® surgical sealant (an anti-adhesive agent) in reducing intra-abdominal adhesions (scar tissue) and the morbidity caused by these adhesions in children treated with a kasai hepatoportoenterostomy. adhesions are common, if not invariable, after any abdominal surgery. they cause intra-abdominal organs to become stuck to each other and the abdominal wall. this means they are no longer completely free to slide over each other. in particular patients have a lifetime risk that the bowel can become kinked or twisted leading to complications such as bowel obstruction. adhesions also make repeat abdominal operations more difficult. the adhesions have to be divided in order to separate the organs from each other and the abdominal wall. this can lead to blood loss and increases the risk of damage to these organs. anti-adhesive agents have been created to reduce the severity of these adhesions, but there is little in the medical literature to evaluate their effectiveness, particularly in children. biliary atresia is an obliterative obstruction of the bile ducts that occurs in infants. initially they are treated by an abdominal operation called a kasai portoenterostomy to restore bile flow from the liver to the intestines. however approximately 40% of these children will go on to require a liver transplant operation in the first two years of life. if coseal® surgical sealant is effective this could reduce the patients lifetime risk of complications from abdominal adhesions and also facilitate repeat abdominal operations for these children, in particular for those who go on to require a liver transplant.


Eligibility criteria:
inclusion criteria: * all patients with biliary atresia undergoing kasai hepatoportoenterostomy. exclusion criteria: * patients with ba and malrotation
local therapies for oligometastatic non-small cell lung cancer harboring sensitizing egfr mutations

Conditions: Oligometastatic Lung Adenocarcinoma

Summary: this study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. this study will also collect blood samples for research blood tests.


Eligibility criteria:
inclusion criteria: * newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring sensitizing egfr mutations (l858r, exon 19 deletion, g719a, l861q, s768i, exon 19 insertions) with oligometastatic disease (≤5 discrete lesions of disease irrespective of location, inclusive of the primary lesion): * all sites of disease must be amenable to definitive treatment with a local therapy (surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy) as determined by surgery, interventional radiology and radiation oncology * all intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular nodal disease) are considered 1 discrete lesion. * each brain metastasis is included as a distinct lesion. * patients already started on erlotinib are eligible as long as their sites of disease are determined to be eligible for definitive local therapy by consensus of the principal investigators within 12 weeks of the patient first taking erlotinib. * lung adenocarcinoma histology confirmed at mskcc. * available archived tissue to perform molecular analysis * patients without available archived tissue can have repeat biopsies to determine egfr status as per standard clinical care guidelines * age 18 years or older * karnofsky performance status ≥ 70% * adequate bone marrow, liver and renal function, as specified below: * absolute neutrophil count (anc) ≥ 1.5 x 109/l * hemoglobin ≥ 8 g/dl * platelets ≥ 100 x 109/l * serum total bilirubin ≤ 1.5 x upper limit of normal (uln) (except for patients with documented gilbert's syndrome) * ast and alt ≤ 2.5 x uln or ≤ 5 x uln if liver metastases are present * serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal. * for women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment * men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter exclusion criteria: * treatment with erlotinib prior to developing metastatic disease * patients with activating but not sensitizing mutations (exon 20 insertions, egfr t790m) * malignant pleural effusion or pleural disease * leptomeningeal disease * any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy * women who are breastfeeding or pregnant * concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment. * any medical co-morbidities that would preclude surgery or radiation therapy

Keywords: sensitizing egfr mutations erlotinib surgery radiation therapy 15-067
cell phone-supported cognitive behavioural therapy

Conditions: Anxiety

Summary: definitions cbt-ubiquitous - cognitive behavioural therapy (cbt) provided with all-time (ubiquitous) support by cell phone applications cbt-tau - cognitive behavioural therapy provided 'as usual' cbt-placebo - cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation. study objectives 1. to compare the relative effectiveness of a computerized ubiquitous cbt (cbt-ubiquitous) against anxiety disorders with cbt-treatment as usual (cbt-tau); 2. to assess the safety and tolerability of the cbt-ubiquitous as compared with cbt-tau and cbt provided with access to a placebo technical device (cbt-placebo).. study implementation the investigators hypothesize that all active treatments are superior to placebo given evidence that face-to-face cbt is effective in the treatment of both anxiety and depression. the investigators also predict that patients receiving cbt-ubiquitous will show greater improvement than those given cbt-tau, and assume that cbt-ubiquitous leads to improved adherence with treatment compared to cbt-tau and cbt-placebo. the investigators will use an intention to treat (itt) approach to fulfill the study aims, by which the investigators mean that clients are analysed as randomized rather than by treatment actually received. the study will be implemented in the central district of östergötland county council (pop 145.000). the research group has in two previous projects (vinnova 2005-2007, vinnova 2008-2009) established cooperation with the 'unga vuxna' (young adults) service provided in this district. the service supplies cbt to the subpopulation experiencing early stages of mental disorders in the age group 16-25 years (n=20,000) in order to prevent development of significant psychiatric disease and disability. the service employs six therapists with at least one year specific cbt training and is co-located with primary healthcare centres (phcs) in downtown linköping, åtvidaberg and kisa. clients staying outside the urban areas can make appointments with therapists at their closest phc on a weekly basis.


Eligibility criteria:
inclusion criteria: * age 18 to 25; and * scoring 7 or higher on the anxiety section of the hospital anxiety and depression scale (hads) at initial evaluation. exclusion criteria: * at the initial evaluation displays symptoms indicative for referral to a psychiatric specialist, e.g. active suicidal ideas or symptoms of a psychotic disorder, organic mental disorder or alcohol and/or drug dependence; or * is unable to read, write or speak in the swedish;

Keywords: cognitive behavioural therapy anxiety primary care effectiveness trial cell-phone supported therapy
study of palifosfamide-tris in combination with doxorubicin in patients with front-line metastatic soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: this is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (sts).


Eligibility criteria:
to be eligible, each patient must meet each of the following criteria: * age ≥18 years. * documented soft tissue sarcoma * metastatic disease for which the patient has not received any prior treatment, and for whom treatment with doxorubicin is considered medically acceptable. * ecog performance status of 0, 1 or 2 * adequate bone marrow and organ function based on the results of protocol- specified laboratory tests * male and female patients must agree to use a highly reliable method of birth control during study participation. * able to provide informed consent to be eligible, each patient must meet none of the following criteria: * specific sarcoma histological subtypes including gist and ewing's sarcoma. * systemic therapy for the treatment of metastatic sarcoma, prior to or during the study. however, patients may have received neo-adjuvant/adjuvant gemzar and taxotere chemotherapy for their primary sarcoma, prior to the development of metastatic disease * any prior anthracycline use. * known allergy to any of the study drugs or their excipients. * any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol). * myocardial dysfunction defined as left ventricular ejection fraction (lvef) \<50%. * documented metastases to brain or meninges. * any malignancy other than sarcoma within the last 5 years prior to screening, with the exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder tumors (ta, tis, or t1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. * currently pregnant or nursing. * radiotherapy with curative intent within 4 weeks of first dose of study drug.

Keywords: metastatic front line
enhancing social interaction with an alterego artificial agent

Conditions: Schizophrenia

Summary: the objective of alterego is the creation of an interactive cognitive architecture, implementable in various artificial agents, allowing a continuous interaction with patients suffering from social disorders, by virtue of changes in behavioural (robot-based) as well as morphological (avatar-based) properties of that agent. the project includes research in fundamental and clinical neurosciences, interaction modeling, development of new computer-vision techniques and human-robot interfaces, as well as evaluation of the scenarios with patients before, during, and after training sessions. at the end of the project, the investigators will produce a new avatar-based clinical method able to enhance social interaction of patients. the first challenge of this project is to create an avatar alter ego of a patient. based on recent work in social robotics and neurosciences, the investigators hypothesize that if patients face artificial agents morphologically and behaviourally similar to them, they will increase their social interaction. the second challenge is to transform the morphology and the behaviour of the similar artificial agent into that of a healthy and different agent. the investigators assume that the smooth and continuous behavioural shift from similar/unhealthy to complementary/healthy social behaviour will lead to a better social rehabilitation. alterego opens the door to a new generation of social artificial agents in service robotics. alterego is an interdisciplinary project at the interaction of social motor neurosciences (um1), robotics (epfl), complex systems dynamics (uob), computer vision (dfki), and psychiatry (chu). this project includes a set of experiments that started in april 2014 and will terminate in september 2016 before undergoing a randomised clinical research.


Eligibility criteria:
inclusion criteria: * patients suffering from schizophrenia according to the criteria proposed in the dsm-iv-tr * aged between 18 and 60 years old. exclusion criteria: * history of head trauma * history of neurological disorders (epilepsy disease, multiple sclerosis, parkinson's disease, amyotrophic lateral sclerosis, huntington's disease, stroke) * an actual ect treatment * substance abuse and / or current substance dependence (excluding tobacco and cannabis). * pregnant women, new mothers and nursing mothers * people private of their liberty